WO1993007885A1 - Antipsoriatic pharmaceutical compositions and process for preparing same - Google Patents
Antipsoriatic pharmaceutical compositions and process for preparing same Download PDFInfo
- Publication number
- WO1993007885A1 WO1993007885A1 PCT/HU1992/000040 HU9200040W WO9307885A1 WO 1993007885 A1 WO1993007885 A1 WO 1993007885A1 HU 9200040 W HU9200040 W HU 9200040W WO 9307885 A1 WO9307885 A1 WO 9307885A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active agent
- grist
- heating
- psoriasis
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Definitions
- This invention relates to novel antipsoriatic pharmaceutical compositions, particularly to novel pharmaceutical compositions useful for healing psoriasis.
- the invention furthermore relates to a process for preparing these compositions.
- Psoriasis is a worldwide occurring disease being particularly frequent in the moderate zone. Both men and women of various ages suffer from this disease. More than 1 % and in Europe 2 - 5 % of the entire population are psoriatic.
- Characteristics of psoriasis are: silvery squamae, desquamation of high grade and a well-circumscribed, round, usually lens-size skin tuber. This tuber occurs most frequently in the knee, elbow and scalp. At present it is recognized that psoriasis is hereditable, which is characteristic of families in some geographical areas. The most characteristic types of psoriasis are: gyrate psoriasis, palm-and-sole psoriasis as well as psoriasis of the scalp.
- the salt-water bathes can be considered to be an important supplementary treatment, chiefly due to the removal of squamae and relieving of the inflammations.
- the present invention is aimed to develop a pharmaceutical composition being useful for healing psoriasis, by which the psoriasis can entirely be ceased without any adverse side effects and the original condition and colour of skin surface can be restored. It has been observed in the course of our experi ⁇ ments that, on carrying out the extraction of wheat grain and/or the grist thereof by pressing and heating, a complex active agent is obtained which, after being formulated to a pharmaceutical composition and used for treatment of the ill psoriatic skin, firstly results in the diminution of the psoriatic skin surface within a short period, then entirely heals it, depending on the severity of the disease and size of the skin surface, within 1-3 month(s) .
- the skin surface has the same consistency and colour as those of the healthy skin and the psoriasis ceases once for all.
- the present invention relates to an anti- psoriatic pharmaceutical composition (being useful for healing psoriasis) , which comprises as active ingredient a complex active agent extract obtained by heating and subsequently pressing wheat grain and/or a grist thereof.
- the novel antipsoriatic compositions are prepared by heating and then pressing wheat grain and/or a grist thereof and subsequently, formulating the thus-obtained complex active agent extract to a therapeutically useful composition, suitably cream, emulsion, gel, tonic or solution.
- a therapeutically useful composition suitably cream, emulsion, gel, tonic or solution.
- the complex active agent is obtained by placing wheat and/or a grist thereof onto a metal plate and pressing it at a temperature between 200 and 800 °C. After mixing with one or more solid and/or liquid carrier(s) and/or additiv (s) , the complex active agent extract is transformed to a cream, emulsion, gel, tonic or solution.
- the composition according to the invention does not contain any other therapeutically active substance in addition to the complex active agent.
- compositions according to the invention known substances such as talc, wheat, maize or potato starch may be employed as solid carriers and one or more therapeutically acceptable liquid solvent(s) , e.g. water, ethanol, and oils of plant or animal origin causing no skin irritation as liquid carrier(s) may be used.
- liquid solvent(s) e.g. water, ethanol, and oils of plant or animal origin causing no skin irritation as liquid carrier(s)
- oleic acid stearic acid or lanolin fatty acid may also be used as liquid carriers.
- Oils or their mixtures commonly used in the cosmetical industry may also be employed as liquid carriers in the compositions according to the invention.
- Menthol and camphor are suitable tonicizing agents.
- distilled or deionized water may be used in an amount of 15 - 70 % calculated for the total weight of the compo ⁇ sition.
- the water amount of creams or ointments is 50-70 %, whereas tonics and solutions preferably contain water in an amount of 30 - 80 %.
- Example 1 The invention is illustrated in detail by the following non-limiting Examples.
- Example 1 The invention is illustrated in detail by the following non-limiting Examples.
- Example 1 The process described in Example 1 is followed.
- the complex active agent extract obtained is dissolved off by 40 % ethanol and further diluted to a solution of 60 %.
- This composition is used for painting.
- the effect of the compositions according to the invention has been proven by the experiments described hereinafter.
- the therapeutically active solution prepared was tested on 20 patients (5 children of 12 - 14 years, 7 women of 18 - 56 years and 8 men of 25 - 72 years) .
- the patients had been psoriatic for seven years in average.
- the patients were treated once daily or every two or three days.
- the ill skin surface healed beginning from the outer edge towards its inside; a ring-like clear streak developed on the skin, which became similar to the colour of skin after 3-5 days. Subsequently, the extension of the ill skin surface was further diminished, the psoriatic part was contracted to a pinhead size and finally, it completely disappeared from the formerly ill skin.
- the duration of treatment is 1-3 month(s) in average; this depends on the size of the ill skin surface, on the interval passed from the beginning of the disase and age of the patients.
- the degree of psoriasis was severe in all cases. The longest period of treatment was three months. After treatment, the psoriasis ceased on all patients (20 persons) , the skin surface became smooth and identical to other skin surfaces of the body.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an antipsoriatic pharmaceutical composition (useful for healing psoriasis), which comprises as active ingredient a complex active agent extract obtained by heating and subsequently pressing wheat grain and/or a grist thereof in admixture with carriers and/or additives commonly used in the pharmaceutical industry. According to the invention, this composition is prepared in such a way that wheat grain and/or a grist thereof is (are) heated by using metal plates and subsequently, the thus-obtained complex active agent extract is transformed in a known way to a cream, emulsion, gel, tonic or solution by mixing it with carriers and/or additives commonly used in the pharmaceutical industry.
Description
ANTIPSORIATIC PHARMACEUTICAL COMPOSITIONS AND PROCESS
FOR PREPARING SAME
This invention relates to novel antipsoriatic pharmaceutical compositions, particularly to novel pharmaceutical compositions useful for healing psoriasis. The invention furthermore relates to a process for preparing these compositions.
Psoriasis is a worldwide occurring disease being particularly frequent in the moderate zone. Both men and women of various ages suffer from this disease. More than 1 % and in Europe 2 - 5 % of the entire population are psoriatic.
Characteristics of psoriasis are: silvery squamae, desquamation of high grade and a well-circumscribed, round, usually lens-size skin tuber. This tuber occurs most frequently in the knee, elbow and scalp. At present it is recognized that psoriasis is hereditable, which is characteristic of families in some geographical areas. The most characteristic types of psoriasis are: gyrate psoriasis, palm-and-sole psoriasis as well as psoriasis of the scalp.
The number of psoriatic people is continuously increasing. One of the most important reasons therefor lies in the phenomenon of the recessive type genetic transmission.
According to the present scientific knowledges,
75910-1815-SZO/KmO
psoriasis can only symptomatically be treated. This is achieved on the one part by diminishing the accelerated growth of epithelial cells and ceasing of the inflamma¬ tion. The use of cytostatics proved to be effective, how¬ ever, due to their toxicity, they can be used for treat¬ ment only twice or three times.
It has been recognized in 1979 and published in 1982 that native terpenes isolated from the rhizome of DRYOPTERIS arrasi or from the leaves and rhizome of POLODIUM vulgare lium, POLIDIUM laucotomos, PLEBODIUM decumanum and CYATHEA tacivaniana are useful to treat psoriatic patients of any sex and age. Hundred fifty two patients were orally treated with daily 200 mg, which resulted in a symptom- ree state lasting 1 - 3 month(s) in 80 % of the treatments.
Recently, the salt-water bathes can be considered to be an important supplementary treatment, chiefly due to the removal of squamae and relieving of the inflammations.
It is obvious from those said above that the healing of psoriasis has not been solved up to the present and the drugs have several side effects.
Thus, the present invention is aimed to develop a pharmaceutical composition being useful for healing psoriasis, by which the psoriasis can entirely be ceased without any adverse side effects and the original condition and colour of skin surface can be restored.
It has been observed in the course of our experi¬ ments that, on carrying out the extraction of wheat grain and/or the grist thereof by pressing and heating, a complex active agent is obtained which, after being formulated to a pharmaceutical composition and used for treatment of the ill psoriatic skin, firstly results in the diminution of the psoriatic skin surface within a short period, then entirely heals it, depending on the severity of the disease and size of the skin surface, within 1-3 month(s) .
The skin surface has the same consistency and colour as those of the healthy skin and the psoriasis ceases once for all.
Thus, the present invention relates to an anti- psoriatic pharmaceutical composition (being useful for healing psoriasis) , which comprises as active ingredient a complex active agent extract obtained by heating and subsequently pressing wheat grain and/or a grist thereof.
According to the invention, the novel antipsoriatic compositions are prepared by heating and then pressing wheat grain and/or a grist thereof and subsequently, formulating the thus-obtained complex active agent extract to a therapeutically useful composition, suitably cream, emulsion, gel, tonic or solution. According to an embodiment of the process of the invention the complex active agent is obtained by placing wheat and/or a grist thereof onto a metal plate and pressing it at a temperature between 200 and 800 °C.
After mixing with one or more solid and/or liquid carrier(s) and/or additiv (s) , the complex active agent extract is transformed to a cream, emulsion, gel, tonic or solution. The composition according to the invention does not contain any other therapeutically active substance in addition to the complex active agent.
For formulation of the compositions according to the invention known substances such as talc, wheat, maize or potato starch may be employed as solid carriers and one or more therapeutically acceptable liquid solvent(s) , e.g. water, ethanol, and oils of plant or animal origin causing no skin irritation as liquid carrier(s) may be used. In addition to these oleic acid, stearic acid or lanolin fatty acid may also be used as liquid carriers.
Oils or their mixtures commonly used in the cosmetical industry, e.g. liquid paraffin, vaseline, coco butter or cod liver oil may also be employed as liquid carriers in the compositions according to the invention. Menthol and camphor are suitable tonicizing agents. In the compositions according to the invention distilled or deionized water may be used in an amount of 15 - 70 % calculated for the total weight of the compo¬ sition. The water amount of creams or ointments is 50-70 %, whereas tonics and solutions preferably contain water in an amount of 30 - 80 %.
The invention is illustrated in detail by the following non-limiting Examples.
Example 1
Wheat grains placed in a single-row layer onto a copper plate with a smooth surface are pressed by an iron plate having a smooth surface of 500 °C temperature. Under the effect of heat and pressure, the complex active agent leaves the wheat and is then washed off with distilled water.
The extract thus obtained is transformed to a solution of 80 % by using distilled water. Example 2
The process described in Example 1 is followed. The complex active agent extract obtained is dissolved off by 40 % ethanol and further diluted to a solution of 60 %. This composition is used for painting. The effect of the compositions according to the invention has been proven by the experiments described hereinafter.
The therapeutically active solution prepared was tested on 20 patients (5 children of 12 - 14 years, 7 women of 18 - 56 years and 8 men of 25 - 72 years) . The patients had been psoriatic for seven years in average.
The patients were treated once daily or every two or three days.
It has been observed during the treatment that after the first treatment an itching, burning sensation occurred, simultaneously the stretching and strain of the skin ceased.
After the second or third treatment, the ill skin
surface healed beginning from the outer edge towards its inside; a ring-like clear streak developed on the skin, which became similar to the colour of skin after 3-5 days. Subsequently, the extension of the ill skin surface was further diminished, the psoriatic part was contracted to a pinhead size and finally, it completely disappeared from the formerly ill skin.
The duration of treatment is 1-3 month(s) in average; this depends on the size of the ill skin surface, on the interval passed from the beginning of the disase and age of the patients.
The time of healing of children is significantly shorter, about the half of that of adults. The healing was evaluated as follows: Child Woman Man
The degree of psoriasis was severe in all cases. The longest period of treatment was three months. After treatment, the psoriasis ceased on all patients (20 persons) , the skin surface became smooth and identical to other skin surfaces of the body.
After the termination of treatment, 1-3-6 mont (s) passed, during this time the patients were symptom-free.
Claims
1. Antipsoriatic pharmaceutical composition (useful for healing psoriasis) which comprises as active ingredient a complex active agent extract, obtained by heating and pressing wheat grain and/or a grist thereof, in admixture with carriers and/or additives commonly used in the pharmaceutical industry.
2. A pharmaceutical composition as claimed in claim 1, which comprises the active agent in an amount of 0.05
- 99.0 % calculated for the total weight of the composi¬ tion.
3. A process for the preparation of an anti¬ psoriatic pharmaceutical composition as claimed in claim 1 or claim 2, which comprises heating and then pressing wheat grain and/or a grist thereof and subsequently, formulating the thus-obtained complex active agent extract to a pharmaceutical composition useful for healing psoriasis, preferably to a cream, emulsion, gel, tonic or solution with carriers and/or additives commonly used in the pharmaceutical industry.
4. A process as claimed in claim 3, which comprises carrying out the heating and pression by using metal plates, suitably iron, copper or aluminium plates.
5. A process as claimed in claim 3 or 4, which comprises carrying out the heating of wheat grain and/or a grist thereof at a temperature range of 200 - 800 °C, suitably at 500 - 600 °C.
6. A process as claimed in any of the claims 3 to 5, which comprises using the active agent in an amount of 0.05 - 99.0 % calculated for the total weight of the composition.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92922168A EP0610306A1 (en) | 1991-10-21 | 1992-10-21 | Antipsoriatic pharmaceutical compositions and process for preparing same |
| FI941800A FI941800L (en) | 1991-10-21 | 1992-10-21 | Anti-psoriasis pharmaceutical compositions and method for their preparation |
| NO941426A NO941426D0 (en) | 1991-10-21 | 1994-04-20 | Antisporatic pharmaceutical preparations and processes for their preparation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU913310A HU207801B (en) | 1991-10-21 | 1991-10-21 | Process for producing pharmaceutical composition for treating psoriasis |
| HU3310/91 | 1991-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1993007885A1 true WO1993007885A1 (en) | 1993-04-29 |
Family
ID=10963524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/HU1992/000040 Ceased WO1993007885A1 (en) | 1991-10-21 | 1992-10-21 | Antipsoriatic pharmaceutical compositions and process for preparing same |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0610306A1 (en) |
| CA (1) | CA2121783A1 (en) |
| FI (1) | FI941800L (en) |
| HU (1) | HU207801B (en) |
| PL (1) | PL307859A1 (en) |
| WO (1) | WO1993007885A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996027019A1 (en) * | 1995-02-25 | 1996-09-06 | Imperial Cancer Research Technology Limited | Transgenic animals as model of psoriasis |
| ES2110921A1 (en) * | 1996-08-08 | 1998-02-16 | Ternum S C C L | Anti-psoriasis composition and procedure for the preparation thereof. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0242794A2 (en) * | 1986-04-22 | 1987-10-28 | ALLRUTAN BIO-PRODUKTE GmbH | Non perishable preparation and process thereof |
| EP0279984A2 (en) * | 1986-12-03 | 1988-08-31 | David Rudov | Pharmaceutical use of graminaceous extracts |
-
1991
- 1991-10-21 HU HU913310A patent/HU207801B/en not_active IP Right Cessation
-
1992
- 1992-10-21 PL PL92307859A patent/PL307859A1/en unknown
- 1992-10-21 CA CA002121783A patent/CA2121783A1/en not_active Abandoned
- 1992-10-21 FI FI941800A patent/FI941800L/en unknown
- 1992-10-21 WO PCT/HU1992/000040 patent/WO1993007885A1/en not_active Ceased
- 1992-10-21 EP EP92922168A patent/EP0610306A1/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0242794A2 (en) * | 1986-04-22 | 1987-10-28 | ALLRUTAN BIO-PRODUKTE GmbH | Non perishable preparation and process thereof |
| EP0279984A2 (en) * | 1986-12-03 | 1988-08-31 | David Rudov | Pharmaceutical use of graminaceous extracts |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996027019A1 (en) * | 1995-02-25 | 1996-09-06 | Imperial Cancer Research Technology Limited | Transgenic animals as model of psoriasis |
| AU698317B2 (en) * | 1995-02-25 | 1998-10-29 | Cancer Research Technology Limited | Transgenic animals as model of psoriasis |
| US6187993B1 (en) | 1995-02-25 | 2001-02-13 | Imperial Cancer Research Technology Limited | Transgenic animals as model of psoriasis |
| ES2110921A1 (en) * | 1996-08-08 | 1998-02-16 | Ternum S C C L | Anti-psoriasis composition and procedure for the preparation thereof. |
Also Published As
| Publication number | Publication date |
|---|---|
| FI941800A7 (en) | 1994-04-19 |
| HU207801B (en) | 1993-06-28 |
| FI941800A0 (en) | 1994-04-19 |
| CA2121783A1 (en) | 1993-04-29 |
| PL307859A1 (en) | 1995-06-26 |
| HU913310D0 (en) | 1992-01-28 |
| FI941800L (en) | 1994-04-19 |
| EP0610306A1 (en) | 1994-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0442982B1 (en) | Topical compositions containing lycd and other topically active medicinal ingredients | |
| US4626433A (en) | Remedy for hemorrhoids | |
| US5869062A (en) | Skin treatment composition | |
| JP3315427B2 (en) | Dermatitis treatment | |
| EP0209724B1 (en) | Preparation effective against acne and the use of an active extract of couch grass | |
| EP0133151A2 (en) | Skin ointment | |
| US4192866A (en) | Anorectal medication | |
| WO2021082298A1 (en) | Composition capable of relieving eczema skin condition, and preparation method therefor | |
| US4515779A (en) | Skin tumor removal and healing compositions and processes | |
| WO1993007885A1 (en) | Antipsoriatic pharmaceutical compositions and process for preparing same | |
| EP0224550B1 (en) | Cosmetic compositions having skin calming and skin regenerating effect and process for the preparation thereof | |
| EP0840613A1 (en) | Synergistic pharmaceutical compositions containing triamcinolone acetonide and halcinonide | |
| CH638681A5 (en) | Pharmaceutical containing Echinacea and lactic acid derivatives and process for its preparation | |
| KR20180055103A (en) | Cosmetic composition for controlling anti-acne comprising Eucalyptus extract | |
| WO1991008750A1 (en) | Use of parts of the natural plant tinospora | |
| EP1399164B1 (en) | Metal salts as antimycotic agents | |
| DE19729143A1 (en) | Herbal ointment for treating dry, flaky skin | |
| CN115770209A (en) | Rod-shaped lithospermum ointment containing three-purple oil and preparation method thereof | |
| DE4010042A1 (en) | USE OF IVY FOR TOPICAL TREATMENT OF INCREASED SCALING OF HAIRY AND HAIRLESS SKIN AND PSORIASIS | |
| DE2015877C3 (en) | Medicines used to treat prostate hypertrophy | |
| US5977176A (en) | Compositions for the treatment of warts and herpes | |
| DK201670336A1 (en) | A Barbados aloe scar eliminating ointment | |
| JPS5984826A (en) | Method for promoting growth of hair in animal | |
| DE3809427A1 (en) | Use of seeds of the neem tree for the prophylaxis and therapy of viral infections | |
| US3629401A (en) | Anti-inflammatory medicinal preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA FI JP KR NO PL RU UA US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1992922168 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 941800 Country of ref document: FI |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2121783 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 1994 211817 Country of ref document: US Date of ref document: 19940624 Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 1992922168 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1992922168 Country of ref document: EP |